(Trospium chloride + xanomeline) is under clinical development by Karuna Therapeutics and currently in Pre-Registration for Schizophrenia. According to GlobalData, Pre-Registration drugs for Schizophrenia have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how (Trospium chloride + xanomeline)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Trospium chloride + xanomeline) overview

Xanomeline in combination with trospium chloride is under development for the treatment of psychosis, negative and cognitive symptoms associated with dementia, dementia-related psychosis, schizophrenia as an adjunctive treatment for psychosis associated with Alzheimer’s disease. It is administered orally as a capsule. The drug candidate act by targeting muscarinic acetyl choline receptors. It was also under development for the treatment of bipolar disorder and pain.

Karuna Therapeutics overview

Karuna Therapeutics is a biopharmaceutical company that focuses on developing medicines for neurological and psychiatric conditions. It is investigating its lead product candidate KarXT, an oral modulator of muscarinic receptors for the treatment of schizophrenia, negative and cognitive symptoms of schizophrenia and Alzheimer’s disease. The company’s other pipeline products include KAR-2618, KAR-401, KAR-501, KAR-201 and KAR-301. Its lead product candidate combines xanomeline, a novel muscarinic agonist that stimulates muscarinic receptors in the central nervous system. Karuna Therapeutics is headquartered in Boston, Massachusetts, the US.

For a complete picture of (Trospium chloride + xanomeline)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.